These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
196 related items for PubMed ID: 16735174
1. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level. Kumar V, Jagannathan NR, Kumar R, Das SC, Jindal L, Thulkar S, Gupta SD, Dwivedi SN, Roell S, Hemal AK, Gupta NP. Magn Reson Imaging; 2006 Jun; 24(5):541-8. PubMed ID: 16735174 [Abstract] [Full Text] [Related]
2. Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. Kumar V, Jagannathan NR, Kumar R, Thulkar S, Gupta SD, Dwivedi SN, Hemal AK, Gupta NP. NMR Biomed; 2007 Aug; 20(5):505-11. PubMed ID: 17167820 [Abstract] [Full Text] [Related]
9. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three Tesla before rebiopsy. Park BK, Lee HM, Kim CK, Choi HY, Park JW. Invest Radiol; 2008 Nov; 43(11):789-93. PubMed ID: 18923258 [Abstract] [Full Text] [Related]
10. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings. Mazaheri Y, Shukla-Dave A, Hricak H, Fine SW, Zhang J, Inurrigarro G, Moskowitz CS, Ishill NM, Reuter VE, Touijer K, Zakian KL, Koutcher JA. Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542 [Abstract] [Full Text] [Related]
11. Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Cirillo S, Petracchini M, Della Monica P, Gallo T, Tartaglia V, Vestita E, Ferrando U, Regge D. Clin Radiol; 2008 Aug; 63(8):871-9. PubMed ID: 18625351 [Abstract] [Full Text] [Related]
13. Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound. Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G. BJU Int; 2008 Aug; 102(4):452-8. PubMed ID: 18476973 [Abstract] [Full Text] [Related]
16. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging. Coakley FV, Chen I, Qayyum A, Westphalen AC, Carroll PR, Hricak H, Chen MH, Kurhanewicz J. BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490 [Abstract] [Full Text] [Related]
17. 1H-MRSI of prostate cancer: the relationship between metabolite ratio and tumor proliferation. Wang XZ, Wang B, Gao ZQ, Liu JG, Liu ZQ, Niu QL, Sun ZK, Yuan YX. Eur J Radiol; 2010 Feb; 73(2):345-51. PubMed ID: 19070978 [Abstract] [Full Text] [Related]
19. Comparison of MRS and DWI in the diagnosis of prostate cancer based on sextant analysis. Li B, Cai W, Lv D, Guo X, Zhang J, Wang X, Fang J. J Magn Reson Imaging; 2013 Jan; 37(1):194-200. PubMed ID: 23002033 [Abstract] [Full Text] [Related]
20. Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Kim CK, Park BK, Lee HM, Kwon GY. Invest Radiol; 2007 Dec; 42(12):842-7. PubMed ID: 18007156 [Abstract] [Full Text] [Related] Page: [Next] [New Search]